The Cancer Letter

Inside information on cancer research and drug development

Drugs & Targets

Legend Biotech, Novartis partner to advance SCLC research

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Legend Biotech Ireland Limited, a wholly owned subsidiary of Legend Biotech, has entered into an exclusive, global license agreement with Novartis Pharma AG for certain Legend Biotech chimeric antigen receptor T-cell therapies targeting DLL3, including its autologous CAR-T cell therapy candidate, LB2102 (NCT05680922).

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Lifileucel shrinks tumors in mNSCLC in phase II trial

Researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute said results of a phase II, multi-center clinical trial revealed that a new type of cell therapy is a promising potential treatment option for patients with stage 4 lung cancer who were previously treated but later developed resistance to other therapies.
Clinical Roundup

CAP publishes guideline for PD-L1 testing for lung cancer

The College of American Pathologists in collaboration with the International Association for the Study of Lung Cancer, Pulmonary Pathology Society, Association for Molecular Pathology, and the LUNGevity Foundation have developed evidence-based recommendations for the testing of immunotherapy biomarkers, including programmed cell death ligand-1 and tumor mutation burden in patients with non-small cell lung carcinoma.
Table of Contents

Login

Site license subscribers:
Log in with your IP | Register a sponsored account